# A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06697197/  
OnCo record `nct06697197` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Nivolumab and Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.

## Summary

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06697197 by Bristol-Myers Squibb, with 413 participants planned, started 2025-02-17 and due to reach its primary completion in 2029-01-04. Interventions recorded: BMS-986482, Nivolumab and rHuPH20, Nivolumab/relatlimab/rHuPH20 and Bevacizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06697197
- Phase: 1/2
- Setting: A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors
- Sponsor: Bristol-Myers Squibb
- Enrolled: 413

## Sources

- ClinicalTrials.gov NCT06697197: https://clinicaltrials.gov/study/NCT06697197

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct06697197.json